Moxidectin

Moxidectin is a potent, broad-spectrum endectocide (antiparasitic that is active against endo- and ecto-parasites) with activity against nematodes, insects, and acari. It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin that is a 16-member pentacyclic lactone of the milbemycin class. Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23. Due to these modifications, moxidectin is classified as a second generation macrocyclic lactone. Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018. It is grouped under the following drug class(es): Anthelmintics and Ectoparasiticides. Its therapeutic use is listed as anti-infectives and antiparasitics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include ProHeart 6, Moxidectina, Moxidectine, Moxidectinum and Cydectin. Its PubChem CID is 9832912.

CAS No 113507-06-5
Molecular Formula C37H53NO8
Molecular Weight 639.80 g/mol
Synonyms (1R,4S,4'E,5'S,6R,6'S,8R,10E,13R,14E,16E,20R,21R,24S)-21,24-dihydroxy-4'-methoxyimino-5',11,13,22-tetramethyl-6'-[(E)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one

Frequently Asked Questions